APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Virus Infection Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Respiratory Virus Infection Drugs Industry Growth and Trends Forecast to 2032

31 December 2025109 pages

Choose your research edition.

Industry ResearchRespiratory Virus Infection Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Virus Infection Drugs Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Respiratory Virus Infection Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Virus Infection Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Virus Infection Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Respiratory Virus Infection Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Virus Infection Drugs include Teva Pharmaceutical Industries Ltd., Sanofi, Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca, Orion Corporation, F. Hoffmann-La Roche Ltd., Cipla, Inc. and CHIESI Farmaceutici S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Respiratory Virus Infection Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Respiratory Virus Infection Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Respiratory Virus Infection Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Respiratory Virus Infection Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Respiratory Virus Infection Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Respiratory Virus Infection Drugs Market by Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Merck and Co., Inc.

GlaxoSmithKline plc

AstraZeneca

Orion Corporation

F. Hoffmann-La Roche Ltd.

Cipla, Inc.

CHIESI Farmaceutici S.p.A.

Boehringer Ingelheim International GmbH

Respiratory Virus Infection Drugs Segment by Type

Nasal Decongestants

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Antibiotics

Cough Suppressants

Others

Respiratory Virus Infection Drugs Segment by Application

Retail Pharmacies

Drug Stores

Hospital Pharmacies

Clinics

Others

Respiratory Virus Infection Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Infection Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Infection Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Infection Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Respiratory Virus Infection Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Nasal Decongestants Table 2. Major Company of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Table 3. Major Company of Antibiotics Table 4. Major Company of Cough Suppressants Table 5. Major Company of Others Table 6. Global Respiratory Virus Infection Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 8. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Type (2021-2026) Table 9. Global Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 10. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Type (2021-2026) Table 11. Global Respiratory Virus Infection Drugs Price by Type (2021-2026) & (US$/Unit) Table 12. Global Respiratory Virus Infection Drugs Sales by Type (2027-2032) & (K Units) Table 13. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Type (2027-2032) Table 14. Global Respiratory Virus Infection Drugs Sales by Type (2027-2032) & (US$ Million) Table 15. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Type (2027-2032) Table 16. Global Respiratory Virus Infection Drugs Price by Type (2027-2032) & (US$/Unit) Table 17. North America Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 18. North America Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 20. Europe Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 24. Latin America Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Respiratory Virus Infection Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Respiratory Virus Infection Drugs Industry Trends Table 28. Respiratory Virus Infection Drugs Industry Drivers Table 29. Respiratory Virus Infection Drugs Industry Opportunities and Challenges Table 30. Respiratory Virus Infection Drugs Industry Restraints Table 31. Global Respiratory Virus Infection Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Respiratory Virus Infection Drugs Revenue Market Share by Company (2021-2026) Table 33. Global Respiratory Virus Infection Drugs Sales by Company (2021-2026) & (K Units) Table 34. Global Respiratory Virus Infection Drugs Sales Share by Company (2021-2026) Table 35. Global Respiratory Virus Infection Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Respiratory Virus Infection Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Respiratory Virus Infection Drugs Major Company Production Sites and Headquarters Table 38. Global Respiratory Virus Infection Drugs Company, Product Type & Application Table 39. Global Respiratory Virus Infection Drugs Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Respiratory Virus Infection Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Respiratory Virus Infection Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Respiratory Virus Infection Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Region (2021-2026) Table 45. Global Respiratory Virus Infection Drugs Sales by Region (2021-2026) & (US$ Million) Table 46. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Region (2021-2026) Table 47. Global Respiratory Virus Infection Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Respiratory Virus Infection Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Region (2027-2032) Table 50. Global Respiratory Virus Infection Drugs Sales by Region (2027-2032) & (US$ Million) Table 51. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Region (2027-2032) Table 52. Global Respiratory Virus Infection Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Respiratory Virus Infection Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 55. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Application (2021-2026) Table 56. Global Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 57. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Application (2021-2026) Table 58. Global Respiratory Virus Infection Drugs Price by Application (2021-2026) & (US$/Unit) Table 59. Global Respiratory Virus Infection Drugs Sales by Application (2027-2032) & (K Units) Table 60. Global Respiratory Virus Infection Drugs Sales Market Share in Volume by Application (2027-2032) Table 61. Global Respiratory Virus Infection Drugs Sales by Application (2027-2032) & (US$ Million) Table 62. Global Respiratory Virus Infection Drugs Sales Market Share in Value by Application (2027-2032) Table 63. Global Respiratory Virus Infection Drugs Price by Application (2027-2032) & (US$/Unit) Table 64. North America Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 65. North America Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 67. Europe Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 71. Latin America Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Respiratory Virus Infection Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Teva Pharmaceutical Industries Ltd. Company Information Table 75. Teva Pharmaceutical Industries Ltd. Business Overview Table 76. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio Table 78. Teva Pharmaceutical Industries Ltd. Recent Development Table 79. Sanofi Company Information Table 80. Sanofi Business Overview Table 81. Sanofi Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Sanofi Respiratory Virus Infection Drugs Product Portfolio Table 83. Sanofi Recent Development Table 84. Merck and Co., Inc. Company Information Table 85. Merck and Co., Inc. Business Overview Table 86. Merck and Co., Inc. Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio Table 88. Merck and Co., Inc. Recent Development Table 89. GlaxoSmithKline plc Company Information Table 90. GlaxoSmithKline plc Business Overview Table 91. GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio Table 93. GlaxoSmithKline plc Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Respiratory Virus Infection Drugs Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Orion Corporation Company Information Table 100. Orion Corporation Business Overview Table 101. Orion Corporation Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Orion Corporation Respiratory Virus Infection Drugs Product Portfolio Table 103. Orion Corporation Recent Development Table 104. F. Hoffmann-La Roche Ltd. Company Information Table 105. F. Hoffmann-La Roche Ltd. Business Overview Table 106. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio Table 108. F. Hoffmann-La Roche Ltd. Recent Development Table 109. Cipla, Inc. Company Information Table 110. Cipla, Inc. Business Overview Table 111. Cipla, Inc. Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio Table 113. Cipla, Inc. Recent Development Table 114. CHIESI Farmaceutici S.p.A. Company Information Table 115. CHIESI Farmaceutici S.p.A. Business Overview Table 116. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio Table 118. CHIESI Farmaceutici S.p.A. Recent Development Table 119. Boehringer Ingelheim International GmbH Company Information Table 120. Boehringer Ingelheim International GmbH Business Overview Table 121. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio Table 123. Boehringer Ingelheim International GmbH Recent Development Table 124. North America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 125. North America Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 126. North America Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2026) Table 127. North America Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 128. North America Respiratory Virus Infection Drugs Sales Market Share Forecast by Country (2027-2032) Table 129. North America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. North America Respiratory Virus Infection Drugs Market Size by Country (2021-2026) & (US$ Million) Table 131. North America Respiratory Virus Infection Drugs Market Share by Country (2021-2026) Table 132. North America Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. North America Respiratory Virus Infection Drugs Market Share Forecast by Country (2027-2032) Table 134. Europe Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 135. Europe Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 136. Europe Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2026) Table 137. Europe Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 138. Europe Respiratory Virus Infection Drugs Sales Market Share Forecast by Country (2027-2032) Table 139. Europe Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Europe Respiratory Virus Infection Drugs Market Size by Country (2021-2026) & (US$ Million) Table 141. Europe Respiratory Virus Infection Drugs Market Share by Country (2021-2026) Table 142. Europe Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Europe Respiratory Virus Infection Drugs Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 146. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2026) Table 147. Asia-Pacific Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 148. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share Forecast by Country (2027-2032) Table 149. Asia-Pacific Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country (2021-2026) & (US$ Million) Table 151. Asia-Pacific Respiratory Virus Infection Drugs Market Share by Country (2021-2026) Table 152. Asia-Pacific Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Asia-Pacific Respiratory Virus Infection Drugs Market Share Forecast by Country (2027-2032) Table 154. Latin America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 155. Latin America Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 156. Latin America Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2026) Table 157. Latin America Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 158. Latin America Respiratory Virus Infection Drugs Sales Market Share Forecast by Country (2027-2032) Table 159. Latin America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Latin America Respiratory Virus Infection Drugs Market Size by Country (2021-2026) & (US$ Million) Table 161. Latin America Respiratory Virus Infection Drugs Market Share by Country (2021-2026) Table 162. Latin America Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Latin America Respiratory Virus Infection Drugs Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2021-2026) & (K Units) Table 166. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share by Country (2021-2026) Table 167. Middle East and Africa Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 168. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share Forecast by Country (2027-2032) Table 169. Middle East and Africa Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Respiratory Virus Infection Drugs Market Share by Country (2021-2026) Table 172. Middle East and Africa Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Middle East and Africa Respiratory Virus Infection Drugs Market Share Forecast by Country (2027-2032) Table 174. Key Raw Materials Table 175. Raw Materials Key Suppliers Table 176. Respiratory Virus Infection Drugs Distributors List Table 177. Respiratory Virus Infection Drugs Customers List Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources Table 181. Primary Sources List of Figures Figure 1. Respiratory Virus Infection Drugs Image Figure 2. Global Respiratory Virus Infection Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Virus Infection Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Virus Infection Drugs Sales (2021-2032) & (K Units) Figure 5. Nasal Decongestants Image Figure 6. Global Nasal Decongestants Sales YoY Growth (2021-2032) & (K Units) Figure 7. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Image Figure 8. Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Sales YoY Growth (2021-2032) & (K Units) Figure 9. Antibiotics Image Figure 10. Global Antibiotics Sales YoY Growth (2021-2032) & (K Units) Figure 11. Cough Suppressants Image Figure 12. Global Cough Suppressants Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Respiratory Virus Infection Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Respiratory Virus Infection Drugs Market Share by Type 2025 VS 2032 Figure 17. North America Respiratory Virus Infection Drugs Sales Market Share in Volume by Type in 2025 Figure 18. North America Respiratory Virus Infection Drugs Sales Market Share in Value by Type in 2025 Figure 19. Europe Respiratory Virus Infection Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Europe Respiratory Virus Infection Drugs Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share in Value by Type in 2025 Figure 23. Latin America Respiratory Virus Infection Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Respiratory Virus Infection Drugs Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Retail Pharmacies Image Figure 30. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 31. Drug Stores Image Figure 32. Global Drug Stores Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Pharmacies Image Figure 34. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Clinics Image Figure 36. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Respiratory Virus Infection Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Respiratory Virus Infection Drugs Market Share by Application 2025 VS 2032 Figure 41. North America Respiratory Virus Infection Drugs Sales Market Share in Volume by Application in 2025 Figure 42. North America Respiratory Virus Infection Drugs Sales Market Share in Value by Application in 2025 Figure 43. Europe Respiratory Virus Infection Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Europe Respiratory Virus Infection Drugs Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Respiratory Virus Infection Drugs Sales Market Share in Value by Application in 2025 Figure 47. Latin America Respiratory Virus Infection Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Respiratory Virus Infection Drugs Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Respiratory Virus Infection Drugs Sales Market Share in Value by Application in 2025 Figure 51. North America Respiratory Virus Infection Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Respiratory Virus Infection Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Respiratory Virus Infection Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Respiratory Virus Infection Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Respiratory Virus Infection Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Respiratory Virus Infection Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Respiratory Virus Infection Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Respiratory Virus Infection Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Respiratory Virus Infection Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Respiratory Virus Infection Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Respiratory Virus Infection Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Respiratory Virus Infection Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Respiratory Virus Infection Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Respiratory Virus Infection Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Respiratory Virus Infection Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Respiratory Virus Infection Drugs Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Respiratory Virus Infection Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Nasal Decongestants
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Antibiotics
  • Cough Suppressants
  • Others
Applications
  • Retail Pharmacies
  • Drug Stores
  • Hospital Pharmacies
  • Clinics
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Merck and Co., Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Orion Corporation
  • F. Hoffmann-La Roche Ltd.
  • Cipla, Inc.
  • CHIESI Farmaceutici S.p.A.
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Virus Infection Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Respiratory Virus Infection Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Respiratory Virus Infection Drugs Market by Type
  6. 1.3.1 Nasal Decongestants
  7. 1.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  8. 1.3.3 Antibiotics
  9. 1.3.4 Cough Suppressants
  10. 1.3.5 Others
  11. 1.4 Global Respiratory Virus Infection Drugs Market Size by Type
  12. 1.4.1 Global Respiratory Virus Infection Drugs Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Respiratory Virus Infection Drugs Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Respiratory Virus Infection Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Respiratory Virus Infection Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Respiratory Virus Infection Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Respiratory Virus Infection Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Respiratory Virus Infection Drugs Industry Trends
  2. 2.2 Respiratory Virus Infection Drugs Industry Drivers
  3. 2.3 Respiratory Virus Infection Drugs Industry Opportunities and Challenges
  4. 2.4 Respiratory Virus Infection Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Respiratory Virus Infection Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Respiratory Virus Infection Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Respiratory Virus Infection Drugs Price (2021-2026)
  4. 3.4 Global Respiratory Virus Infection Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Virus Infection Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Respiratory Virus Infection Drugs Company, Product Type & Application
  7. 3.7 Global Respiratory Virus Infection Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Virus Infection Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Virus Infection Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Virus Infection Drugs Tier 1, Tier 2, and Tier 3
4 Respiratory Virus Infection Drugs Regional Status and Outlook
  1. 4.1 Global Respiratory Virus Infection Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Respiratory Virus Infection Drugs Historic Market Size by Region
  3. 4.2.1 Global Respiratory Virus Infection Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Respiratory Virus Infection Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Respiratory Virus Infection Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Respiratory Virus Infection Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Respiratory Virus Infection Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Respiratory Virus Infection Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Respiratory Virus Infection Drugs by Application
  1. 5.1 Respiratory Virus Infection Drugs Market by Application
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Clinics
  6. 5.1.5 Others
  7. 5.2 Global Respiratory Virus Infection Drugs Market Size by Application
  8. 5.2.1 Global Respiratory Virus Infection Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Respiratory Virus Infection Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Respiratory Virus Infection Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Respiratory Virus Infection Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Respiratory Virus Infection Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Respiratory Virus Infection Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Respiratory Virus Infection Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd.
  2. 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Respiratory Virus Infection Drugs Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Merck and Co., Inc.
  14. 6.3.1 Merck and Co., Inc. Company Information
  15. 6.3.2 Merck and Co., Inc. Business Overview
  16. 6.3.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio
  18. 6.3.5 Merck and Co., Inc. Recent Developments
  19. 6.4 GlaxoSmithKline plc
  20. 6.4.1 GlaxoSmithKline plc Company Information
  21. 6.4.2 GlaxoSmithKline plc Business Overview
  22. 6.4.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio
  24. 6.4.5 GlaxoSmithKline plc Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Respiratory Virus Infection Drugs Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Orion Corporation
  32. 6.6.1 Orion Corporation Company Information
  33. 6.6.2 Orion Corporation Business Overview
  34. 6.6.3 Orion Corporation Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Orion Corporation Respiratory Virus Infection Drugs Product Portfolio
  36. 6.6.5 Orion Corporation Recent Developments
  37. 6.7 F. Hoffmann-La Roche Ltd.
  38. 6.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 6.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 6.7.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio
  42. 6.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 6.8 Cipla, Inc.
  44. 6.8.1 Cipla, Inc. Company Information
  45. 6.8.2 Cipla, Inc. Business Overview
  46. 6.8.3 Cipla, Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio
  48. 6.8.5 Cipla, Inc. Recent Developments
  49. 6.9 CHIESI Farmaceutici S.p.A.
  50. 6.9.1 CHIESI Farmaceutici S.p.A. Company Information
  51. 6.9.2 CHIESI Farmaceutici S.p.A. Business Overview
  52. 6.9.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio
  54. 6.9.5 CHIESI Farmaceutici S.p.A. Recent Developments
  55. 6.10 Boehringer Ingelheim International GmbH
  56. 6.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 6.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 6.10.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio
  60. 6.10.5 Boehringer Ingelheim International GmbH Recent Developments
7 North America by Country
  1. 7.1 North America Respiratory Virus Infection Drugs Sales by Country
  2. 7.1.1 North America Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Respiratory Virus Infection Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Respiratory Virus Infection Drugs Market Size by Country
  6. 7.2.1 North America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Respiratory Virus Infection Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Respiratory Virus Infection Drugs Sales by Country
  2. 8.1.1 Europe Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Respiratory Virus Infection Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Respiratory Virus Infection Drugs Market Size by Country
  6. 8.2.1 Europe Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Respiratory Virus Infection Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Respiratory Virus Infection Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Respiratory Virus Infection Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Respiratory Virus Infection Drugs Sales by Country
  2. 10.1.1 South America Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Respiratory Virus Infection Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Respiratory Virus Infection Drugs Market Size by Country
  6. 10.2.1 South America Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Respiratory Virus Infection Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Respiratory Virus Infection Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Respiratory Virus Infection Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Respiratory Virus Infection Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Respiratory Virus Infection Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Respiratory Virus Infection Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Respiratory Virus Infection Drugs Value Chain Analysis
  2. 12.1.1 Respiratory Virus Infection Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Respiratory Virus Infection Drugs Production Mode & Process
  7. 12.2 Respiratory Virus Infection Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Respiratory Virus Infection Drugs Distributors
  10. 12.2.3 Respiratory Virus Infection Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst